Sanofi nabs U.S. rights to a safer aspirin in $35M Pozen deal

Sanofi ($SNY) is handing over a $15 million upfront payment along with promises of $20 million in precommercialization milestones to partner with Chapel Hill, NC-based Pozen ($POZN) on a pair of new-and-improved aspirins that avoid some common side effects. The therapies combine immediate-release omeprazole, a proton pump inhibitor, and enteric-coated aspirin in a single tablet, PA8140 and PA32540. The pharma giant gets U.S. commercialization rights in the deal. "The PA products have the potential to be an effective solution for the millions of patients at risk for gastric ulcers from chronic aspirin use in the prevention of secondary cardiovascular disease," said Sanofi's North American president, Anne Whitaker. Release

Suggested Articles

The deal gives J&J a stake in the development and commercialization of anticoagulants including phase 2-ready secondary stroke candidate BMS-986177.

Boehringer gained the global rights to OSE's SIRP-alpha antagonist, which is in development for solid tumors.

Lilly is diving into encapsulated beta cell treatments, designed to restore insulin production in patients with Type 1 diabetes.